Testa vår nya webbplats och uppdaterade nyhetsrum för att ta del av aktuella nyheter, rapporter och mycket mer.

Communiqué from extraordinary general meeting in Emplicure AB (publ)

An extraordinary general meeting in Emplicure AB (publ) (the "Company") was held on Monday 14 November 2022 at 11 am at the Company's premises, Virdings allé 32B, Uppsala.

At the general meeting, the following resolutions were made:

Resolution regarding approval of the transfer of shares in the subsidiary Amplicon AB to Amplicon's CEO Tomas Hammargren

It was resolved to approve that the company transfers shares in the subsidiary Amplicon AB to Tomas Hammargren on the following terms:

  • Tomas Hammargren or a company wholly owned by Tomas Hammargren is offered to acquire 1,250 shares in Amplicon, corresponding to five percent of the total number of outstanding shares in Amplicon.
  • The price for the shares amounts to a total of SEK 805,000, which corresponds to the board's assessed market value. The board's assessment is based on a valuation of Amplicon carried out by BDO on behalf of the Company.
  • The transfer shall be conditional on Emplicure and Tomas Hammargren entering into a customary shareholder agreement.

The resolution was supported by shareholders holding more than 9/10 of the votes cast and the shares represented at the general meeting.

For additional information, please contact

Gisela Sitbon

Chairman of the Board
Phone: +46 70 282 55 58
Email: [email protected]

Erik Magnusson

CFO
Phone: +46 708 565 245
Email: [email protected]

Certified Adviser

Emplicure AB (publ) is listed on the Nasdaq First North Growth Market. Certified Adviser is Erik Penser Bank.

Emplicure develops new and innovative products by combining existing and approved active substances with advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain and on abuse-deterrent formulations. The subsidiary Amplicon AB develops consumer products with oral nicotine as the first product. The share is listed on Nasdaq First North Growth Market (EMPLI). Read more at www.emplicure.com

Emplicure och OnDosis samarbetar för att utveckla bättre behandlingar för smärta

Emplicure AB och OnDosis AB utvärderar gemensamma utvecklingsmål för oral dosering av aktiva ingredienser baserade på bolagens respektive kärnkompetenser inom formulering och dosering.


Emplicure and OnDosis form partnership to develop better pain treatments

Emplicure and OnDosis will jointly evaluate development targets for oral delivery of active ingredients, based on their respective core competencies in formulation and dosing.


Emplicure meddelar resultat från den explorativa kliniska farmakokinetiska studien på sin läkemedelskandidat Empli03

Emplicure AB, företaget som kombinerar egen teknologi med beprövade substanser och ingredienser för att utveckla nya konsument- och läkemedelsprodukter, tillkännager idag topline-resultat från en explorativ farmakokinetisk studie med Empli03 på friska försökspersoner.


Emplicure announces results from the exploratory clinical PK study of its drug candidate Empli03

Emplicure, the company that combines proprietary technology with tried and tested substances and ingredients to develop new consumer and pharmaceutical products, today announces top-line results from an exploratory pharmacokinetic study with Empli03 in healthy volunteers


Emplicure anlitar Erik Penser Bank som likviditetsgarant

Emplicure AB (publ) har utsett Erik Penser Bank AB ("Penser") till likviditetsgarant för Bolagets aktie. Syftet är att förbättra aktiens likviditet och Pensers uppdrag inleds den 24 november 2022.


Emplicure engages Erik Penser Bank as liquidity provider

Emplicure AB (publ) today announced that the company has entered into an agreement with Erik Penser Bank ("Penser") whereby Penser will act as liquidity provider for the Emplicure share, starting 24 November 2022.




Kommuniké från extra bolagsstämma i Emplicure AB (publ)

Extra bolagsstämma i Emplicure AB (publ) ("Bolaget") ägde rum kl. 11.00 måndagen den 14 november 2022 i Bolagets lokaler, Virdings allé 32B, Uppsala.


Communiqué from extraordinary general meeting in Emplicure AB (publ)

An extraordinary general meeting in Emplicure AB (publ) (the "Company") was held on Monday 14 November 2022 at 11 am at the Company's premises, Virdings allé 32B, Uppsala.


Emplicure upptar lån om 9,0 MSEK

Emplicure AB (publ) har idag ingått ett låneavtal med ett konsortium av långivare genom vilket Bolaget upptagit ett lån om 9,0 MSEK. Lånekonsortiet inkluderar vissa befintliga aktieägare, däribland styrelseledamoten Johan Wieslander. Syftet med lånet är att kortsiktigt stärka bolagets rörelsekapital samt att möta kravet på befintligt aktiekapital för att driva bolaget den närmaste tolvmånadersperioden.


Emplicure takes up a loan in the amount of 9.0 MSEK

Emplicure AB (publ) has today entered into a loan agreement with a loan consortium through which the Company has taken up a loan in the amount of 9.0 MSEK. The loan consortium includes certain existing shareholders, including the board member Johan Wieslander. The purpose of the loan is to strengthen the Company's short-term working capital and to meet the requirement of going concern for the next twelve months.




Emplicure utser valberedning

Emplicure AB meddelar idag att valberedningen har utsetts inför stämman i maj 2023. Valberedningen består av representanter för de tre största aktieägarna per den sista bankdagen i tredje kvartalet, jämte styrelsens ordförande. Bolagets tre största aktieägare, tillika grundare, har enats om att rösta som en genom Thomas Lundqvist, för att ge företräde till oberoende aktieägare.


Emplicure has formed Nomination Comittee

Emplicure AB announces today that the Nomination Committee for the annual general shareholders meeting (AGM) in May 2023 is formed. The Nomination Committee  consists of representatives nominated by the three largest shareholders per the last bank-day in the third quarter, as well as the Chairman of the Board. Emplicure's three largest shareholders, also the founders, have agreed to vote as one, in order to give preference for more shareholders.


Dosering i fas I PK-studie för EMPLI03 slutförd

Emplicure AB rapporterar genomförd dosering i den första fas I farmakokinetikstudien med EMPLI03, avsedd för behandling av medelsvår till svår smärta


Dosing in Phase I PK study for EMPLI03 completed

Emplicure AB today reported dosing in the first Phase I pharmacokinetic study for EMPLI03, intended for the treatment of moderate to severe pain


Emplicure byter Certified Adviser till Erik Penser Bank AB

Uppsala 2022-10-03 Emplicure AB (publ) meddelade idag att bolaget byter Certified Adviser


Emplicure changes Certified Adviser to Erik Penser Bank AB

Uppsala, 2022-10-03 Emplicure AB (publ) today announced that the company changes Certified Adviser


Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Nybrogatan 34
Box 5216
102 45 Stockholm

08-692 21 90

Om beQuoted